Adc Therapeutics SA (ADCT) Implied Volatility Current

Tracking ADCT implied volatility helps you identify when options premiums on Adc Therapeutics SA are historically cheap or expensive, and where the best trades are hiding. Adc Therapeutics SA implied volatility reflects the market's expectation of future price movement: when ADCT IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Adc Therapeutics SA's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For ADCT, tracking metrics like ADCT IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on ADCT signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors.

In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where ADCT implied volatility sits today versus where it has been. Our scanner ranks Adc Therapeutics SA implied volatility against its historical range, surfaces extremes in ADCT IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Adc Therapeutics SA IV is rich or cheap — measure it, then act on it.